戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tumours, consistent with the inactivation of dihydropyrimidine dehydrogenase: a selective decrease in
2 Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-
3 ples include thiopurine S-methyltransferase, dihydropyrimidine dehydrogenase and flavin monooxygenase
4             5-Fluorouracil is inactivated by dihydropyrimidine dehydrogenase and targets thymidylate
5                                              Dihydropyrimidine dehydrogenase catalyzes the rate-limit
6 bolite 5-methyl tetrahydrofolate (MTHF), and dihydropyrimidine dehydrogenase (DPD) activity in periph
7                                              Dihydropyrimidine dehydrogenase (DPD) activity was deter
8                                              Dihydropyrimidine dehydrogenase (DPD) catabolizes endoge
9                                              Dihydropyrimidine dehydrogenase (DPD) deficiency constit
10 cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which
11                                              Dihydropyrimidine dehydrogenase (DPD) is a major determi
12                                              Dihydropyrimidine dehydrogenase (DPD) is the initial and
13                                              Dihydropyrimidine dehydrogenase (DPD) is the initial, ra
14 ve reported a correlation between intratumor dihydropyrimidine dehydrogenase (DPD) messenger RNA (mRN
15 ected dose of 5-FU is rapidly inactivated by dihydropyrimidine dehydrogenase (DPD) to therapeutically
16 ficiency of the pyrimidine catabolic enzyme, dihydropyrimidine dehydrogenase (DPD), has been shown to
17 e uracil in UFT slows degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD), which results in
18                                              Dihydropyrimidine dehydrogenase (DPD, encoded by DPYD) r
19  in the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie, DPYD*2A) is st
20 ral regimen of eniluracil (which inactivates dihydropyrimidine dehydrogenase [DPD]), 5-FU, and leucov
21  enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on
22 n addition, AEG-1 enhances the expression of dihydropyrimidine dehydrogenase (DPYD) that catalyzes th
23                                              Dihydropyrimidine dehydrogenase (DPYD), a pyrimidine-deg
24 red study with eniluracil, an inactivator of dihydropyrimidine dehydrogenase, enabling catabolite cor
25                        Thus, by inactivating dihydropyrimidine dehydrogenase, EU prolonged the half-l
26                                      Tumoral dihydropyrimidine dehydrogenase expression is a promisin
27 acy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS H
28  shown the prognostic impact of several rare dihydropyrimidine dehydrogenase gene (DPYD) variants on
29                                          The dihydropyrimidine dehydrogenase gene (DPYD) was isolated
30 e to progression (TTP) of an oral regimen of dihydropyrimidine dehydrogenase inhibitory fluoropyrimid
31                      Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XE
32 pidermal growth factor receptor mutation, or dihydropyrimidine dehydrogenase polymorphism) may differ
33  and other drug metabolizing enzymes such as dihydropyrimidine dehydrogenase represents a major innov
34 acil (776C85) is an effective inactivator of dihydropyrimidine dehydrogenase that allows continuous l
35 acil is being developed as an inactivator of dihydropyrimidine dehydrogenase, the enzyme that brings
36 routine use of p53, ras, thymidine synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。